Treatment outcomes for patients with metastatic castrate‐resistant prostate cancer following docetaxel for hormone‐sensitive disease

Abstract

Aim Optimal treatment for newly diagnosed metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved, with many patients deriving benefit from the addition of docetaxel to androgen deprivation therapy (D‐ADT). This study sought to define the therapy used and associated activity following D‐ADT. Methods Retrospective analysis of patients with mHSPC treated with one or more cycles of D‐ADT who were identified from a prospectively maintained multisite prostate cancer database of patients treated in a community or academic center setting in Australia. The primary endpoint of this study was first‐line time to treatment failure (1L TTF) for subsequent treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC), with secondary endpoints of prostate‐specific antigen (PSA) reduction >50% and time from 1L to second‐line (2L) treatment initiation. Results A total of 93 patients received D‐ADT for mHSPC, 85 (91%) had subsequent treatment for mCRPC. Median time to mCRPC (biochemical, clinical or radiographic) had been 14.8 months (95% confidence interval [CI], 11.9–16.5). 1L treatment was enzalutamide 47 patients (55%), abiraterone 23 (27%), cabazitaxel 7 (8%), docetaxel 4 (5%) and other therapies 4 (5%). Median 1L TTF was 6.3 months (95% CI, 4.9–7.6), PSA > 50% reduction was achieved in 32 of 89 patients (36%), median time from 1L to second‐line treatment was 7.3 months (1.3–27.4), which did not differ significantly between treatment groups. Conclusions Abiraterone, enzalutamide, cabazitaxel and docetaxel all demonstrate activity following progression on D‐ADT. No difference in efficacy was detected between treatment options for mCRPC. Prospective trials investigating the optimal treatment sequence for prostate cancer following progression on D‐ADT needed.

Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers

“…Docetaxel is also a member of the taxane class of anticancer drugs. Docetaxel alone or docetaxel-based regimens are employed in standard chemotherapy for various types of cancers [54,55]. A study showed that prolonged exposure to docetaxel and 5-fluorouracil (5-FU) in colon cancer cells (HT29 and LOVO cell lines) under hyperglycemia led to decreased anticancer effects of these drugs, and suppression of mROS production [32].…”

Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer

“…It is one of the most common cancers of the male genitourinary system worldwide and has a high incidence among male malignant tumors [1][2][3]. In patients with localized prostate cancer (LPCa), radical prostatectomy, radiotherapy and hormone deprivation therapy can markedly beneficial effects, prolonging the survival time of patients [4][5][6][7][8][9][10]. However, due to the lack of obvious symptoms and specific biomarkers in the early stage of PCa metastasis, the diagnosis and treatment of metastatic prostate cancer (MPCa) is commonly delayed.…”